grant
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors
Organization ROSWELL PARK CANCER INSTITUTE CORPLocation BUFFALO, UNITED STATESPosted 9 Jun 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY2025Abscopal effectAcute Radiation SyndromeAddressAfter CareAfter-TreatmentAftercareAgonistAntibodiesBlood NeutrophilBlood Polymorphonuclear NeutrophilCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCT-26CT26Cancer CauseCancer EtiologyCancer PatientCancersCell Communication and SignalingCell DeathCell SignalingCell surfaceCessation of lifeClinicClinicalClinical DataColonColorectal CancerCombined Modality TherapyCytoplasmDeathDiseaseDisorderDrugsEnsureExpression SignatureFDA approvedFlagellinGene Expression ProfileGeneticGoalsHepatic CellsHepatic Neoplasm SecondaryHepatic Parenchymal CellHepatic metastasisHepatocyteHumanIFN-GammaIFN-gIFN-γIFNGIFNγImmuneImmune InterferonImmune Modulation TherapyImmune mediated therapyImmunesImmunologically Directed TherapyImmunomodulationImmunoradiotherapyImmunotherapeutic agentImmunotherapyInflammasomeInjectionsInnovative TherapyInterferon GammaInterferon Type IIIntracellular Communication and SignalingIrradiated tumorLettersLinkLiverLiver CellsLiver secondariesLiver secondary cancerMalignant MelanomaMalignant NeoplasmsMalignant TumorMarrow NeutrophilMeasuresMediatingMedicationMelanomaMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the LiverMetastatic TumorMetastatic Tumor to the LiverMetastatic malignant neoplasm to liverMiceMice MammalsModelingModern ManMultimodal TherapyMultimodal TreatmentMurineMusNeoplasm MetastasisNeutrophilic GranulocyteNeutrophilic LeukocyteNormal TissueNormal tissue morphologyOperative ProceduresOperative Surgical ProceduresOutcomePD-1 antibodyPD1 antibodyPathway interactionsPatientsPharmaceutical PreparationsPhasePolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPre-Clinical ModelPreclinical ModelsPublishingRadiationRadiation ToxicityRadiation therapyRadioimmunotherapyRadiotherapeuticsRadiotherapyRadiotoxicityResearchRodentRodentiaRodents MammalsSafetySalmonellaSamplingSecondary NeoplasmSecondary TumorShapesSignal TransductionSignal Transduction SystemsSignalingSiteSourceSurgicalSurgical InterventionsSurgical ProcedureT cell responseT8 CellsT8 LymphocytesTIL3TLR5TLR5 geneTLR5 receptorTestingTimeToll-Like Receptor 5Toll/Interleukin-1 Receptor-Like Protein 3TranslatingTreatment EfficacyTumor ImmunityWorkaCTLA-4aCTLA-4 antibodiesaCTLA4aPD-1aPD1abscopal activityabscopal responseanti programmed cell death 1anti-CTLA-4anti-CTLA-4 antibodiesanti-CTLA4anti-CTLA4 antibodiesanti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor immunityantiPD-1antitumor immunitybiological signal transductioncancer immunitycancer metastasischeck point blockadecheckpoint blockadecolon cancer metastasiscombination therapycombined modality treatmentcombined treatmentcytokinedrug/agenteffective therapyeffective treatmentgene expression patterngene expression signaturegene signaturesgenetic signaturehealthy volunteerhepatic body systemhepatic organ systemimmune check point blockadeimmune checkpoint blockadeimmune drugsimmune microenvironmentimmune modulationimmune modulatory therapiesimmune modulatory treatmentimmune regulationimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmuno therapyimmunologic reactivity controlimmunologic therapeuticsimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatoryimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulationimmunoregulatoryimmunoregulatory therapyimmunoregulatory treatmentimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimprovedinnovateinnovationinnovativeintervention efficacylFN-Gammaliver metastasesmalignancymalignant liver neoplasm, specified as secondarymetastasis in the livermetastasis to the livermetastasize to the livermetastatic cancer to livermetastatic livermetastatic liver neoplasmmulti-modal therapymulti-modal treatmentnecrocytosisneo-antigenneo-epitopesneoantigensneoepitopesneoplasm/cancerneutrophilnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-human primatenonhuman primatenovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathwaypharmacologicpost treatmentpre-clinicalpre-clinical therapypreclinicalpreclinical therapyradiation poisoningradiation treatmentresponseresponse to therapyresponse to treatmentsecondary liver malignancysecondary malignant liver neoplasmsurgerysurvival outcometherapeutic efficacytherapeutic immunomodulationtherapeutic immunoregulationtherapeutic outcometherapeutic responsetherapy efficacytherapy outcometherapy responsetoll-5 receptortranscriptional profiletranscriptional signaturetreatment responsetreatment responsivenesstreatment with radiationtumortumor cell metastasistumor immune microenvironmenttumor-immune system interactionsα-CTLA-4α-CTLA4αCTLA-4αCTLA4αPD-1αPD1
Description preview
The liver is a frequent site of metastasis for several cancers and when this occurs, it is associated with poor
response to immunotherapy. Liver-directed radiotherapy (RT) is a non-traditional immune modulating therapy
that improves immune checkpoint blockade (ICB, αPD-1 or αPD-1/αCTLA-4) mediated control of liver metastasis
and non-irradiated…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click